Blinatumomab may induce graft versus host leukemia in patients with pre-B ALL relapsing after hematopoietic stem cell

Muhammad Waqas Khan1, Zartash Gul1

  • 1Department of Internal medicine Division of Hematology/Bone Marrow Transplantation University of Kentucky Lexington Kentucky.

Clinical Case Reports
|August 16, 2016
PubMed

Blinatumomab, a bispecific T-cell engager monoclonal antibody used to manage Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) can be used to treat patients by inducing graft versus leukemia reaction post allogeneic hematopoietic stem cell transplantation, a feature which it was post allogeneic bone marrow transplantation, a feature which this drug was not aimed to do.